Research indicates that structured weight loss support prior to in vitro fertilisation (IVF) can enhance pregnancy rates for women living with obesity. Approximately one in five women of childbearing age are classified as obese, defined by the World Health Organization as having a body mass index (BMI) exceeding 30 kg/m2. Compared to women within the healthy BMI range of 18.5 to 24.9 kg/m2, those with obesity face a tripled risk of fertility issues and nearly double the likelihood of miscarriage.
In a comprehensive study, data from twelve international trials involving a total of 1,921 women seeking IVF was analyzed. The research focused on comparing the outcomes of those who received structured weight loss programmes with those who received standard care, which typically lacks such support. Findings revealed that women who engaged in a weight loss programme had a 21% higher chance of conceiving, whether naturally or through IVF. Notably, the probability of achieving a natural conception increased by 47%, allowing some women to forgo fertility treatments altogether.
Despite these promising pregnancy rates, the research did not establish a clear link between weight loss support and improved live birth rates. This gap may stem from the fact that many studies included in the analysis did not track live birth outcomes, which are often the most critical measure for patients.
Addressing Eligibility and Access to IVF
In the UK, publicly funded IVF is typically restricted to women with a BMI below 30, a policy mirrored in various countries. Such weight-based eligibility criteria disproportionately affect women from lower socioeconomic backgrounds and certain ethnic groups, creating a paradox where those most likely to require IVF are often less likely to qualify for it.
While some women can afford private weight loss programmes to meet the BMI requirements, others resort to unproven or potentially harmful methods to achieve rapid weight loss, jeopardizing their health in the process. The research suggests that implementing structured weight loss programmes for women with obesity who are ineligible for IVF could significantly improve their chances of conception and, in some instances, eliminate the need for IVF entirely.
This approach not only promotes equitable access to fertility treatment but also offers better value for healthcare providers, as the cost of weight loss support is relatively low compared to the expenses associated with IVF.
Effective Weight Loss Options
Among the most promising non-surgical options for significant weight loss are medications known as GLP-1 receptor agonists, including Wegovy and Mounjaro. These medications have demonstrated substantial weight reduction in clinical studies. However, they are not recommended for use during pregnancy, while attempting to conceive, or during breastfeeding due to insufficient safety data and potential risks to fetal development observed in animal studies.
For women planning to conceive soon, alternative, safe options exist, such as structured support groups and low-energy diet programmes. Unfortunately, these services are often not included in standard IVF care. In some cases, existing weight management programmes within the National Health Service (NHS) have limited access, lengthy waiting lists, and are primarily aimed at individuals with obesity-related health conditions, rather than those pursuing fertility treatment. Similar trends are noted in other countries, where insurance coverage for weight loss support is inconsistent, necessitating private funding that may be out of reach for those in need.
The findings from this research underscore the importance of targeted weight loss initiatives before IVF. Such programmes not only enhance the prospects of achieving pregnancy but could also reduce the reliance on IVF, promote fairness in access to fertility treatment, and conserve healthcare resources. The challenge remains to ensure these supportive programmes are available to all women who require them, rather than just those who can afford to pay.
The authors of the study have declared no financial ties or conflicts of interest with any companies or organizations that would benefit from these findings, maintaining their objectivity in the research.
